CEO Leon O. Moulder Jr. purchased 20,000 shares at $18.23, signaling confidence in the stock's recovery potential despite recent losses. This move coincides with a widening quarterly net loss and a 46% decline over the last 90 days, yet insiders are betting on the commercial launch of obexelimab.
Price context
ZBIO is currently trading at $19.55, down 46.16% over the last 90 days and 56.17% below its 52-week high of $44.60. The stock has experienced significant volatility, having gained 147.47% over the past year before the recent pullback.
Catalysts to watch
- •The company reported Q1 2026 results on May 13, showing a net loss of $80.99 million.
- •A $250 million non-dilutive loan agreement secured on March 17 supports the commercialization and development of obexelimab.
- •Follow-on equity and convertible notes offerings completed on March 29 are earmarked for the planned U.S. commercial launch of obexelimab.
Risks
- •The stock carries significant risk with a short interest of 26.1% of the float.
- •Additionally, the company reported a sharply wider quarterly net loss of $80.99 million in Q1 2026 compared to $33.57 million a year ago.
AI-generated context from public data. Not investment advice. Verify before trading.